2-pyridone antimicrobial compositions
Disclosed herein are compounds of Formula I wherein R 1 , R 2 , X, and Y are defined herein. These compounds are type II topoisomerase inhibitors and can be used in methods for treating infections caused by gram-positive pathogens, gram-negative pathogens, and drug-resistant strains thereof.
1. A method of treating a bacterial infection in a subject, the method comprising administering to a subject in need thereof an effective amount of a compound having the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
X is, C 1-8 alkyl, C 1-8 alkoxy, or —N(R X ) 2 , wherein each R X is independently hydrogen, C 1-8 alkyl, or C 1-8 haloalkyl;
Y is pyridyl optionally substituted with one group which is —N(R Y1 ) 2 or —C 1-8 alkyl—N(R Y1 ) 2 , and optionally substituted by one to two groups that are each independently halogen, C 1-8 alkyl, —R Y , or C 1-8 alkyl—R Y ;
R Y is nitro, cyano, —OR Y1 , —SR Y1 , —N(R Y1 ) 2 , —C(O)R Y1 , —C(O)OR Y1 , —C(O)N(R Y1 ) 2 , —OC(O)R Y1 , —OC(O)OR Y1 , —OC(O)N(R Y1 ) 2 , —N(R Y1 )C(O)R Y1 , —N(R Y1 )C(O)OR Y1 , —N(R Y1 )C(O)N(R Y1 ) 2 , —S(O) 2 R Y1 , —S(O) 2 OR Y1 , —S(O) 2 N(R Y1 ) 2 , —OS(O) 2 R Y1 , —OS(O) 2 OR Y1 , —OS(O) 2 N(R Y1 ) 2 , —N(R Y1 )S(O) 2 R Y1 , —N(R Y1 )S(O) 2 R Y1 , or —N(R Y1 )S(O) 2 N(R Y1 ) 2 ; and
R Y1 is independently hydrogen, C 1-8 alkyl, or C 1-8 haloalkyl.
2. The method of claim 1 , wherein Y is pyridyl substituted with one group which is —NH 2 or —CH 2 NH 2 .
3. The method of claim 1 , wherein the bacterial infection is caused by a pathogen selected from the group consisting of Acinetobacter baumannii, Bacillus anthracis, Brucella abortus, Burkholderia cepacia, Burkholderia mallei, Burkholderia pseudomallei, Burkholderia thailandensis, Citrobacter freundii, Cornyebacterium jeikeium, Enterobacter sp, Enterobacter cloacae, Enterococcus faecium, Enterococcus gallinarum, Francisella tularensis, Klebsiella aerogenes, Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Neisseria meningitides, Proteus mirabilis, Providencia stuartii, Serratia marcescens, Shigella sp, Staphylococcus haemolyticus, Staphylococcus saprophyticus, Stenotrophomonas maltophilia, Streptococcus agalactiae, Streptococcus bovis, Streptococcus constellatus, Streptococcus mitis, Streptococcus pyogenes, Streptococcus oxalis, Streptococcus sanguis , Group C HStreptococcus, Yersinia pestis, Staphylococcus aureus, Staphylococcus epidermis, Streptococcus pneumoniae, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenza.
4. The method of claim 1 , wherein the pathogen is selected from the group consisting of Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Haemophilus influenza, Stenotrophomonas maltophilia, Bacillus anthracis, Brucella abortus, Burkholderia mallei, Burkholderia pseudomallei, Francisella tularensis, and Yersinia pestis.
5. A compound of the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
X is, C 1-8 alkyl, C 1-8 alkoxy, or —N(R X ) 2 , wherein each R X is independently hydrogen, C 1-8 alkyl, or C 1-8 haloalkyl;
Y is pyridyl optionally substituted with one group which is —N(R Y1 ) 2 or —C 1-8 alkyl—N(R Y1 ) 2 , and optionally substituted by one to two groups that are each independently halogen, C 1-8 alkyl, —R Y , or C 1-8 alkyl—R Y ;
R Y is nitro, cyano, —OR Y1 , —SR Y1 , —N(R Y1 ) 2 , —C(O)R Y1 , —C(O)OR Y1 , —C(O)N(R Y1 ) 2 , —OC(O)R Y1 , —OC(O)OR Y1 , —OC(O)N(R Y1 ) 2 , —N(R Y1 )C(O)R Y1 , —N(R Y1 )C(O)OR Y1 , —N(R Y1 )C(O)N(R Y1 ) 2 , —S(O) 2 R Y1 , —S(O) 2 OR Y1 , —S(O) 2 N(R Y1 ) 2 , —OS(O) 2 R Y1 , —OS(O) 2 OR Y1 , —OS(O) 2 N(R Y1 ) 2 , —N(R Y1 )S(O) 2 R Y1 , —N(R Y1 )S(O) 2 R Y1 , or —N(R Y1 )S(O) 2 N(R Y1 ) 2 ; and
R Y1 is independently hydrogen, C 1-8 alkyl, or C 1-8 haloalkyl.
6. The compound of claim 5 , wherein Y is pyridyl substituted with one group which is —NH 2 or —CH 2 NH 2 .